Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin.

@article{Ling2014CytochromeP3,
  title={Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin.},
  author={Spencer Y Ling and Robert B. Huizinga and Patrick Mayo and Richard Larouche and Derrick G. Freitag and Launa J. Aspeslet and Robert Thomas Foster},
  journal={British journal of clinical pharmacology},
  year={2014},
  volume={77 6},
  pages={
          1039-50
        }
}
AIMS Voclosporin is a novel calcineurin inhibitor intended for prevention of organ graft rejection and treatment of lupus nephritis. Pharmacokinetic drug interactions between voclosporin and a CYP3A inhibitor, inducer and substrate and a P-glycoprotein inhibitor and substrate were evaluated. METHODS Voclosporin 0.4 mg kg(-1) was administered to 24 subjects in each of five studies, as follows: every 12 h (Q12H) alone and concomitantly with ketoconazole 400 mg once daily (QD); single dose… CONTINUE READING
BETA
2
Twitter Mentions

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 25 REFERENCES

The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation.

  • American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2011